Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119401
Author
Miyazaki, Katsuki Beckman Research Institute of City of Hope Comprehensive Cancer Center|Tokushima University
Xu, Caiming Beckman Research Institute of City of Hope Comprehensive Cancer Center|Dalian Medical University
Goel, Ajay Beckman Research Institute of City of Hope Comprehensive Cancer Center
Keywords
curcumin
andrographis
glutathione peroxidase 4
ferroptosis suppressor protein 1
natural products
colorectal cancer
Content Type
Journal Article
Description
Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide. The limitations of current chemotherapeutic drugs in CRC include their toxicity, side effects, and exorbitant costs. To assess these unmet needs in CRC treatment, several naturally occurring compounds, including curcumin and andrographis, have gained increasing attention due to their multi-targeted functionality and safety vs. conventional drugs. In the current study, we revealed that a combination of curcumin and andrographis exhibited superior anti-tumor effects by inhibiting cell proliferation, invasion, colony formation, and inducing apoptosis. Genome-wide transcriptomic expression profiling analysis revealed that curcumin and andrographis activated the ferroptosis pathway. Moreover, we confirmed the gene and protein expression of glutathione peroxidase 4 (GPX-4) and ferroptosis suppressor protein 1 (FSP-1), the two major negative regulators of ferroptosis, were downregulated by this combined treatment. With this regimen, we also observed that intracellular accumulation of reactive oxygen species and lipid peroxides were induced in CRC cells. These cell line findings were validated in patient-derived organoids. In conclusion, our study revealed that combined treatment with curcumin and andrographis exhibited anti-tumorigenic effects in CRC cells through activation of ferroptosis and by dual suppression of GPX-4 and FSP-1, which have significant potential implications for the adjunctive treatment of CRC patients.
Journal Title
Pharmaceuticals
ISSN
14248247
Publisher
MDPI
Volume
16
Issue
3
Start Page
383
Published Date
2023-03-02
Rights
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences